ArticleCell death & disease2026
Hypoxia-induced PLOD3 activates the NEDD4/GOT2 axis to exacerbate renal cell carcinoma progression.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating renal cell carcinoma (RCC) is clinically challenging because the characteristic hypoxic microenvironment of RCC serves as a key driver of malignant progression. High-throughput sequencing analysis across multiple models was used in this study to identify PLOD3 as a major oncogene driving RCC development. PLOD3 promoted RCC cell growth and metastatic capacity in vivo and in vitro. Mechanistically, HIF-2α and histone lactylation modification jointly upregulate PLOD3 expression levels. PLOD3 specifically binds to the C2 domain of NEDD4, hindering NEDD4 autoinhibition and triggering NEDD4 to activate E3 ubiquitin ligase function. This process affects GOT2 expression via inducing K48-linked ubiquitination, leading to GOT2 degradation via the ubiquitin-proteasome pathway. Thus, PLOD3 participates in reprogramming glutamine metabolism through influencing the stability GOT2 protein. This study establishes PLOD3 as a key oncogenic driver of RCC, with HIF-2α/PLOD3/NEDD4/GOT2 pathway potentially being a therapeutic target and providing biomarkers for treating RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.